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Abstract
Introduction: Malignant ascites is often a sign of a terminal stage in several malignant diseases. To
control ascites, drainage and intra-abdominal chemotherapy are often used in those patients but
eradication of ascites is difficult and prognosis is poor.
Case presentation: A 55-year-old woman was admitted to our hospital on 26 January 2007 with
dyspnea, abdominal distention and oliguria. Abdominocentesis revealed peritoneal carcinomatosis
resulting from abdominal recurrence from lung cancer. To alleviate the dyspnea and abdominal
distention, we drained the ascites aseptically and infused them intravenously back into the patient
after removal of tumor cells by centrifugation, and then concentration by apheresis. After the
drainage of ascites, we intraperitoneally infused activated killer cells and dendritic cells from the
patient's tumor-draining lymph nodes, together with 4.5 × 105U interleukin-2 in 50 ml saline by 2.1
ml/hour infuser balloon.
Drastic decreases in the tumor cell count and in ascite retention were observed after several
courses of ascites drainage, intravenous infusion and intraperitoneal immunotherapy. The plasma
protein level was maintained during the treatment notwithstanding the repeated drainage of ascites.
Cell surface marker analysis, cytotoxic activities against autologous tumor cells and interferon-
gamma examination of ascites suggested the possibility that these effects were mediated by
immunological responses of activated killer cells and dendritic cells infused intraperitoneally.
Conclusion: Combination of local administration of immune cells and infusion of concentrated cell
free ascites may be applicable for patients afflicted with refractory ascites.
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Introduction
Malignant ascites is often a sign of terminal stage in sev-
eral malignant diseases. It represents one of the most com-
mon causes of death in patients with digestive
malignancies with an overall median survival of 3 to 6
months [1-6]. These patients are considered as being in
the terminal phase of their diseases and they receive palli-
ative or symptomatic treatments. Abdominocentesis and
drainage alleviate symptoms caused by ascites such as
abdominal distention, dyspnea and oliguria, but cause
hypovolemia, hypoproteinemia and general malaise. To
control ascites, drainage and intra-abdominal chemother-
apy are often employed for those patients, but eradication
of ascites is difficult and the prognosis is poor.
In this study, we report on a patient with peritoneal carci-
nomatosis caused by a recurrence of lung cancer that was
successfully treated with abdominocentesis, reinfusion of
concentrated ascites and adoptive immunotherapy with
dendritic cells and activated killer cells.
Case presentation
A 52-year-old woman underwent right upper lobectomy
of primary lung adenocarcinoma after induction chemo-
therapy on 2 November 2004. Histological examination
revealed pleural dissemination, intrapulmonary metasta-
sis (PM2) and mediastinal lymph node metastasis
(pT4N2M1 stage IV). She received nine courses of adju-
vant chemotherapy, 7 of intrathoracic immunotherapy
(1.82 × 1010 cells) and 12 of intravenous immunotherapy
(5.6 × 1010 cells) with dendritic cells and activated killer
cells (DC+AK) obtained from long-term tissue cultures of
regional lymph nodes of lung cancer. She was admitted to
our hospital for dyspnea, abdominal distention and olig-
uria on 26 January 2007. The abdominocentesis revealed
peritoneal carcinomatosis resulting from abdominal
recurrence from lung cancer.
To alleviate dyspnea and abdominal distention, we
drained ascites aseptically and infused it back to the
patient intravenously after removal of tumor cells by cen-
trifugation and concentration by apheresis (apheresis
monitor KM-8900, Kuraray Medical Co. Tokyo Japan).
Before infusion, the endotoxin of ascites was quantified
and those samples with less than 3 pg/ml endotoxin were
used.
The methods for in vitro culture of dendritic cells and acti-
vated killer cells have been described elsewhere [7].
Briefly, regional lymph nodes with no metastasis
obtained during surgery for the primary lung cancer were
minced aseptically into blocks of about 1 mm3 and sus-
pended in KBM-400 serum-free lymphocyte culture
medium (Kojin Bio, Tokyo, Japan) with 400 IU inter-
leukin 2 (IL2; Proleukin Chiron B.V., Amsterdam, Nether-
lands). Two weeks later, the tumor draining lymph node
(TDL) tissue culture was transferred to a CO2 gas permea-
ble culture bag, and every 3 to 4 days, fresh medium was
added. When dendritic cells and activated killer cells were
released from the lymph node tissue, cells were harvested
and tissue culture continued until the release of new cells
ceased (dormant phase). The tissue started to produce
DC+AK cells when one to two billion (1–2 × 109) periph-
eral blood lymphocytes were added to the culture at this
dormant phase. Using this procedure, we obtained a total
of 1.54 × 1011 DC+AK cells.
We also used cells from ascites (tumor infiltrating lym-
phocytes, TIL) obtained after DC+AK immunotherapy.
The TIL were washed three times in PBS and cultured in
KBM-400 lymphocyte medium for 2 weeks.
As a control for cytotoxic tests, we cultured regional
lymph nodes from another patient with lung cancer (48-
year-old man, T4N2M0, stage IIIB adenocarcinoma) in
IL2 for 1 month. The significant cytotoxic activity of the
activated killer cells of this patient (MT-116) had already
been confirmed against autologous tumor cells.
Cytological examination of the ascites before and after
treatment was carried out using Papanicolaou stain. We
also examined quantitatively the numbers of tumor cells
in ascites before and after the treatment.
Cytokine concentration of IFN-gamma, TGF-beta, and
IL12 in ascites was measured by a Sandwich ELISA Kit
(Chemicon International, Inc., CA, USA) before, and 8
hours, 24 hours, 48 hours and 5 days after the first intra-
peritoneal immunotherapy.
The cytotoxic activity of TIL obtained from ascites was
determined by the 51Cr-releasing test. One million tumor
cells were labeled with 3.7MBq sodium chromate-51Cr
(Na2
51CrO4; Daiichi Radioisotope Lab. Ltd., Tokyo,
Japan) for 45 minutes, washed three times with culture
medium and suspended at 1 × 105/ml. Effector lym-
phocytes obtained from ascites after immunotherapy
were cultured in IL2 for 2 weeks, washed and counted. The
cells were suspended at 1 × 107 cells/ml. In sterile glass
tubes, 0.2 ml samples of labeled tumor cells (2 × 104)
were mixed with serial dilutions of effector cells (2 × 106
to 2.5 × 105) in 0.2 ml of medium. The effector target cell
mixture was incubated at 37°C in a 5% CO2 atmosphere
for 4 hours. Two milliliters of cold medium was added at
the termination of incubation, centrifuged at 900 g for 10
minutes and the radioactivity of the supernatant was
examined with a gamma counter (Auto-well Gamma Sys-
tem; ARC-370, Aloka, Tokyo, Japan). The cytotoxic activ-
ity was calculated with the following formula:Journal of Medical Case Reports 2008, 2:372 http://www.jmedicalcasereports.com/content/2/1/372
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Cytotoxic activity (%) = (CPM of test – CPM of medium
control)/(CPM of Maximum control – CPM of medium
control) ×100,
where medium control was measured in medium alone
without effector cells and maximum control was counted
in 0.2 ml of 1 N HCl instead of effector cells. All of the
tests were performed in quadruplicate.
The cell surface markers of mononuclear cells were deter-
mined by a fluorescence-activated cell sorter with various
monoclonal antibodies: CD3, CD4, CD8, CD83, and
HLA-DR.
From 16 February 2007, we drained 3000 ml of ascites
from the hypogastric area every week for 1 month. A total
of 13,222 ml of ascites was aspirated from this area (Fig-
ure 1a). Then, from 23 March 2007, we drained a total of
6000 ml of ascites from the epigastric area over a period
of 3 weeks (Figure 1b).
A total of 2480 ml of concentrated ascites was infused
back into the patient six times (Figures 1a and 1b) and this
was equivalent to 4808 ml of 4.4% albumin. The constit-
uents of ascites before and after apheresis are listed in
Table 1. The protein and albumin of ascites were concen-
trated 3 to 4 times but electrolytes, blood urea nitrogen
(BUN), creatinine and uric acid were dialyzed through the
membrane. The plasma protein concentration was main-
tained between 5.5 and 6.2 g/dl during the patient's hos-
pital stay notwithstanding the repeated drainage of ascites
(Table 2). Chills and fever for 20 to 30 minutes beginning
soon after the initiation of infusion were the only side
effects of this treatment.
Surface markers of cells obtained from long-term tissue
culture of tumor-draining lymph nodes (TDL) of the
patient and tumor-infiltrated lymphocytes (TIL) obtained
from the ascites after immunotherapy, were determined
by fluorescence-activated cell-sorting (FACS) using mono-
clonal antibodies (Table 3). Cells from TDL consist
mainly of CD8-positive and CD4-positive T cells and
CD83-positive dendritic cells. TIL consists mainly of CD8-
positive T cells.
After the second drainage of ascites, we infused 5.4 × 109
DC+AK cells intraperitoneally accompanied by 4.5 × 105U
IL2 in a 50 ml saline infuser balloon (2.1 ml/hour;
Surefuser A; Nipro, Tokyo, Japan, Figure 1). Three days
later, 2200 ml ascites was drained and the number of
tumor cells was counted. A drastic decrease in the tumor
cell count (1/77) was observed; from 4.6 × 108 cells in
3000 ml to 6 × 106 cells in 2200 ml ascites (Figure 2a). The
third treatment with 7.6 × 109 DC+AK and IL2 revealed
Volume of ascites and number of transferred cells Figure 1
Volume of ascites and number of transferred cells: (a) Volume of ascites drained and number of DC+AK cells trans-
ferred into the hypogastric area. From 16 February 2007 (day 1), we started to drain 3000 ml of ascites and transferred 5.4 × 
109 DC+AK cells on day 8. Drainage and intraperitoneal immunotherapy in the hypogastric area continued for 1 month. A total 
of 13,222 ml of ascites was aspirated. Black bars indicate the volume of ascites, and white arrows, the date of DC+AK immu-
notherapy. (b) Volume of ascites drained and number of DC+AK cells transferred into the epigastric area. From 23 March 
2007 (day 1), we started to drain 2800 ml of ascites and transferred 9.8 × 109 DC+AK cells on day 5. Drainage and intraperito-
neal immunotherapy in the epigastric area continued for 1 month. A total of 6000 ml of ascites was aspirated. Black bars indi-
cate the volume of ascites, and white arrows, the date of DC+AK immunotherapy. The gray arrow indicates the date of TIL 
immunotherapy.Journal of Medical Case Reports 2008, 2:372 http://www.jmedicalcasereports.com/content/2/1/372
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complete disappearance of the ascitic fluid in the
hypogastric area. The treatment of the epigastric area with
9.8 × 109 DC+AK and 4.5 × 105U IL2 reduced the tumor
cell count from 6.6 × 108 to 6 × 105 (1/1100; Figures 1b
and 2a). After the first treatment of the epigastric area, we
cultured lymphocytes obtained from ascites in KBM-400
serum-free lymphocyte culture medium for 2 weeks. Cyto-
logical examination, analysis of the cell surface markers
(Table 3) and a cytotoxicity test against autologous tumor
cells (Figure 2b) indicated that TIL consists of cytotoxic T
cells without tumor cell contamination. We inoculated
2.8 × 109 TIL along with 2.7 × 109 DC+AK intraperito-
neally (Figure 1b). After this treatment, ascite retention
stopped and tumor cells were not found cytologically.
The cytokine concentration of IFN-gamma (Table 4), TGF-
beta, and IL12 in ascites were measured before, and 8
hours, 24 hours, 48 hours and 5 days after the first intra-
peritoneal immunotherapy. Although the concentrations
of TGF-beta and IL12 did not change during the period
(data not shown), that of IFN-gamma increased signifi-
cantly up to 400 pg/ml 8 hours after the initiation of the
first immunotherapy. The concentration of IFN-gamma
decreased gradually with time to 130 pg/ml 5 days later.
The cytotoxic activity of TIL and other effector cells (MT-
116) against tumor cells obtained from ascites was deter-
mined (Figure 2b). TIL showed a high cytotoxic activity
against autologous target cells, but allogeneic effector cells
(MT-116) failed to show activity against the same target
cells.
Cytological examination was carried out before and after
intraperitoneal immunotherapy. Before the treatment,
ascites consisted exclusively of carcinoma cells varying in
size with prominent nucleoli forming papillary pattern
clusters (Figure 3a). After treatment, most of the cells
turned out to be lymphocytes. Cell surface marker analy-
sis indicated that most of the infiltrates were CD4-, and
CD3-positive T cells (Figure 3b). The patient survived for
more than 10 months after the initiation of therapy.
Discussion
In this report, we present a case in which intractable
malignant ascites was successfully treated by dendritic
cell-activated killer cell immunotherapy and infusion of
cell-free concentrated ascites to the patient. Malignant
ascites that causes dyspnea, abdominal distention and
retention of water in the body is often a sign of the termi-
nal stage of cancer. Drainage of ascites induces a transient
relief of symptoms but also induces hypoproteinemia,
hypovolemia and a further retention of ascites. To main-
tain the serum protein level and give longer relief from the
symptoms, we infused concentrated cell-free, endotoxin-
free ascites back into the patient. By this procedure, the
serum protein level was maintained between 5.5 and 6.2
g/dl, notwithstanding the repeated drainage of ascites
once a week for 2 months. Chills and fever for 20 to 30
minutes beginning soon after the initiation of infusion,
were the only side effects of this treatment. There were no
changes of serum BUN, creatinine, electrolyte, bilirubin,
or transaminase after the infusion of concentrated ascites.
Since tumor cells were removed by centrifugation and fil-
tration through a PS filter, pulmonary metastasis was not
observed after the treatment.
This patient received 9 courses of adjuvant chemotherapy,
7 courses of intrathoracic immunotherapy (1.82 × 1010
DC+AK cells) and 12 courses of intravenous immuno-
therapy (5.6 × 1010 DC+AK cells) obtained from long-
term tissue cultures of the regional lymph nodes of lung
cancer. Despite the pleural dissemination, intrapulmo-
nary metastasis (PM2) and mediastinal lymph node
metastasis (T4N2M1 stage IV), intrathoracic recurrence
was prevented for 2 years. Peritoneal recurrence may
result from an insufficient immunotherapeutic effect in
the abdominal cavity. Intravenous and intrathoracic inoc-
ulation of immune cells causes accumulation of effector
cells in the thoracic cavity, but not in the abdominal cav-
ity. Intra-abdominal inoculation of dendritic cells and
Table 1: Constituents of ascites before and after apheresis
23 February 13 March
Before After Before After
Total protein (g/dl) 4.71 21.19 4.73 14.04
Albumin (g/dl) 2.78 12.92 2.59 7.97
BUN (mg/dl) 18.7 12.6 12.7 3.7
Creatinine (mg/dl) 0.65 0.47 0.57 0.2
Uric acid (mg/dl) 7.6 6.7 6.9 2.9
Total cholesterol (mg/dl) 135 421 125 370
A S T  ( I U / l ) 1 77 9 1 77 4
ALT (IU/l) 6 25 6 14
LDH (IU/l) 559 2336 517 2124
Gamma-GTP (IU/l) 48 61 39 48
ALP (IU/l) 787 825 464 589
Na (mEq/l) 138 141 140 146
K (mEq/l) 3.5 2.7 3.1 1.2
Cl (mEq/l) 102 85 102 105
Total Bil (mg/dl) 0.5 2.6 1.5 4.7
Direct Bil (mg/dl) 0.1 0.3 0.4 0.6
CRP (mg/dl) 1.9 8 1.4 5.4
Endotoxin (pg/ml) 2.23 <3 1.87 <3
Table 2: Plasma protein and albumin levels during treatment
19 February 26 February 9 March 12 April
Total protein (g/dl) 6.2 6 6 6.3
Albumin (g/dl) 3.3 3.4 3.3 3.3Journal of Medical Case Reports 2008, 2:372 http://www.jmedicalcasereports.com/content/2/1/372
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activated killer cells decreased the number of tumor cells
drastically. The precise mechanisms of eradication of
tumor cells by the adoptive transfer of activated killer T
cells and DCs are not clear, but it may be mediated mainly
by the immune responses of cytotoxic killer T cells since
an abrupt increase in IFN-gamma in ascites occurred after
the treatment, cytotoxic activity of infiltrating T cells was
detected against autologous tumor cells in ascites, and
most of the cells recovered from the ascites after treatment
were CD3-, CD4-, and CD8-positive T cells.
Although it is very difficult to apply these treatments to
other patients with lung cancer, because recurrence only
in the abdominal cavity as malignant ascites is very rare,
further study is necessary to analyze the efficacy and
mechanisms of this exploratory treatment.
Conclusion
To control ascites, drainage and intra-abdominal chemo-
therapy are applied in most cases. However, complete
eradication of ascites is difficult, and the prognosis of
advanced cases of ascites is generally 2 to 3 months. The
combination of local administration of immune cells and
infusion of concentrated cell-free ascites may be applica-
ble for patients afflicted with refractory ascites.
Abbreviations
DC+AK: dendritic cells and activated killer cells; ELISA:
enzyme-linked immunosorbent assay; IFN-gamma: inter-
feron gamma; IL2: interleukin 2; IL12: interleukin 12;
TDL: tumor draining lymph nodes; TGF-beta: transform-
ing growth factor beta; TIL: tumor infiltrating lym-
phocytes.
(a) Number of tumor cells obtained from ascites Figure 2
(a) Number of tumor cells obtained from ascites. From 16 February 2007 (day 1), we started to drain 3000 ml of ascites and 
counted the number of tumor cells in the hypogastric area. After the second drainage of ascites, we infused DC+AK cells intra-
peritoneally with IL2. Three days later, 2200 ml of ascites was drained and the number of tumor cells was counted. A drastic 
decrease in the tumor cell count (1/77) was observed: from 4.6 × 108 cells to 6 × 106 cells. From 23 March (day 36), we initi-
ated drainage from the epigastric area. The number of tumor cells decreased from 6.6 × 108 (day 36) to 0 (day 71) after the 
fifth immunotherapy with DC+AK cells and TIL. (b) Cytotoxic activity of autologous and allogeneic effector cells. Cytotoxic 
activity of TIL was examined by the 51Cr-releasing test. Tumor cells obtained from ascites were labeled with Na2
51CrO4, incu-
bated with autologous effector (TIL) cells and allogeneic effector (MT-116) cells. 51Cr release was counted with a gamma coun-
ter. TIL showed a high cytotoxic activity against autologous tumor cells (black filled diamond), but MT-116 did not (black filled 
square).
Table 3: Cell surface markers of DC+AK and TIL
DC+AK TIL
CD3 99.2 98.9
CD8 38.2 97.3
CD4 68.2 7
HLA-DR 97.9 95.7
CD83 19.1 2
Table 4: Concentration of IFN γ in the ascites (pg/ml ± SD*)
Before 8 hours 24 hours 48 hours 5 days
23 ± 4 401 ± 27 383 ± 1 272 ± 9 130 ± 14
*SD, standard deviation.Journal of Medical Case Reports 2008, 2:372 http://www.jmedicalcasereports.com/content/2/1/372
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Cytological findings of ascites Figure 3
Cytological findings of ascites. (a) Papanicolaou stain of ascites on 9 February 2007 (before treatment). Carcinoma cells 
varying in size with prominent nucleoli form papillary pattern clusters. (b) Papanicolaou stain of ascites on 18 April 2007 (after 
treatment). Most of the infiltrates are small lymphocytes and carcinoma cells are not present. Cell surface marker analysis indi-
cated that most of the cells were CD4- and CD3-positive T cells (data not shown).Publish with BioMed Central    and   every 
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Consent
Informed consent for this therapy was obtained from the
patient. She died 10 months after the initiation of this
therapy. We obtained written informed consent for publi-
cation of this case report from the patient's next-of-kin. A
copy of the written consent is available for review by the
Editor-in-Chief of this journal.
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